Adherium’s appearance in The Australian and Stockhead’s Investor Guide

30 Sep 2022 | Investors

Adherium has been included in The Australian and Stockhead’s ‘Investor Guide: Health and Biotech FY23’.

We thank both publications for this opportunity to share the company profile and investor highlights.

The Australian - Stockhead Investor Guide Health and Biotech 2022.pdf

Previous Next

This website uses cookies that have security, network management and accessibility functions. You can disable them in your browser settings, but this may affect your experience of the website. Click here to find out more.